PPARG and pancreatic neoplasm: Other investigators reported an increase of PAI-1 (Plasminogen Activator Inhibitor 1) and a decrease in cell invasion in pancreatic cancer cell lines treated with rosiglitazone or pioglitazone but these effects seemed to be independent of PPARγ activation because they were observed even in cell lines that did not express the nuclear receptor [54].